Novartis hands over $55M upfront to license preclinical hives prospect from Japan's Kyorin - Fierce Biotech
  KYORIN and Cyrano Therapeutics Enter into an Option Agreement for CYR-064 for the Treatment of Post-Viral Loss of Smell in Japan - PR Newswire
  With Dupixent nipping at its heels, Novartis bets up to $777M on Kyorin's itch candidate - FirstWord Pharma
  KYORIN and Novartis Forge Global License Agreement for KRP-M223 - TipRanks
  Kyorin offers Novartis timely new weapon in urticaria - The Pharma Letter
  Novartis gains rights to Kyorin’s chronic spontaneous urticaria candidate in deal worth $830m - PMLiVE
  Kyorin partners Hyfe to develop DTx for chronic cough - Pharmaphorum
  Kyorin drafts deals for chronic cough DTx, loss of smell therapy - BioWorld MedTech